Home > News > Clinical Data Presented at ESMO
November 8th, 2004
Clinical Data Presented at ESMO
Abstract:
ACLARA BioSciences today announced that Sharat Singh, Ph.D., ACLARA's Chief Technical Officer, presented data from a pilot clinical trial demonstrating the ability of ACLARA's eTag(TM) assays to correctly differentiate responders from non-responders to Herceptin(R) treatment in patients with breast cancer. These data, subject to confirmation in larger, trials, suggest that the eTag System may be more accurate than the current standard at differentiating responders from non-responders to this widely used targeted therapy.
Source:
ACLARA BioSciences
Related News Press |
Possible Futures
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||